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ABSTRACT
Cryptococcosis, a systemic disease caused by the fungus Cryptococcus neoformans/ 
Cryptococcus gattii is more severe in immunocompromised individuals. This study aimed 
to analyze the epidemiology of the disease, the molecular characteristics and the antifungal 
susceptibility of C. neoformans isolated from patients treated in a Brazilian university 
hospital. This retrospective study was conducted in the Clinical Hospital, Federal University 
of Uberlândia, and evaluated cases of cryptococcosis and strains of C. neoformans isolated 
from 2004 to 2013. We evaluated 41 patients, 85% of whom were diagnosed with AIDS. 
The fungus was isolated from the cerebrospinal fluid (CSF) of 21 patients (51%); 19.5% 
had fungemia and in 24% the agent was isolated from the CSF and blood, concurrently. 
Meningoencephalitis was the most frequent (75%) manifestation of infection. Despite 
adequate treatment, the mortality of the disease was 58.5%. Most isolates (97.5%) presented 
the VNI genotype (serotype A, var. grubii) and one isolate was genotyped as C. gattii (VGI); 
all the isolates were determined as mating type MATα and showed susceptibility to the 
tested antifungals (fluconazole, voriconazole, amphotericin B and 5-flucytosine). Although 
AIDS detection rates remain stable, opportunistic infections such as cryptococcosis remain 
as major causes of morbidity and mortality in these patients.
KEYWORDS: Cryptococcus neoformans. Cryptococcosis. Molecular typing. Antifungal 
susceptibility testing.
INTRODUCTION
Fungi of the complex Cryptococcus neoformans/Cryptococcus gattii are 
encapsulated, cosmopolitan yeasts, and are able to infect and cause disease in many 
hosts, including man1. Cryptococcosis, an illness caused by these microorganisms, is 
a systemic disease that may be subacute or chronic and potentially fatal, and primarily 
affects the meninges. Its occurrence was rare before the acquired immunodeficiency 
syndrome (AIDS) epidemic, and was usually associated with patients presenting 
low cellular immunity2. As a global causative agent, C. neoformans is estimated to 
cause more than one million new cases of cryptococcosis a year with about 625,000 
deaths3. C. neoformans is usually associated with immunocompromised individuals 
(AIDS patients, neutropenic individuals and those receiving prolonged therapy with 
corticosteroids); C. gattii is more often associated with immunocompetent patients4.
Cryptococcus neoformans has serotypes A, D and AD; in contrast, C. gattii 
that has serotypes B and C. The former species also presents two varieties related 
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to serotypes var. grubii (serotype A) and var. neoformans 
(serotype D)5,6. Serotype A predominates in clinical and 
environmental isolates in most areas, except in Northern 
European countries, where serotype D accounts for 
50% of the isolates7. Serotype AD was isolated from the 
environment and in patients in North America and Europe8. 
Until recently, the accepted idea was that C. gattii was 
restricted to tropical and subtropical areas. However, an 
outbreak in Vancouver Island, Canada, reported in 2002, 
changed assumptions about the pattern of distribution of 
this species9.
The treatment of cryptococcosis has been the subject of 
numerous studies. Currently, only three classes of antifungal 
drugs have been considered for this purpose: the polyenes 
(amphotericin B), the azoles (ketoconazole, itraconazole, 
fluconazole and voriconazole) and a pyrimidine-derived 
drug (5- flucytosine)10. The latter is not available in Brazil. 
However, some of the drugs administered to treat fungal 
infections have high failure rates, and the emergence 
of fungal intrinsic resistance is a growing problem11,12. 
Regarding the treatment of HIV-positive patients with 
fungal infections of the mucous membranes, in the period 
preceding the introduction of antiretroviral therapy, the 
repeated and prolonged use of azoles favored the acquisition 
of drug resistance in several fungal pathogens, including 
C. neoformans13.
The aims of this study were to evaluate the 
epidemiological profile of patients who had developed 
cryptococcosis and to determine their susceptibility 
to antifungal drugs, and also to explore the molecular 
characteristics of C. neoformans isolated from patients 
treated at the Clinical Hospital of the Federal University 
of Uberlândia (HCU) from 2004 to 2013. 
MATERIALS AND METHODS 
In this retrospective study, 41 strains of Cryptococcus 
that had been previously identified as C. neoformans were 
included. They were isolated from patients treated at the 
Clinical Hospital of Uberlândia from 2004 to 2013. These 
strains were stored in the Clinical Laboratory of that 
institution from the time of diagnosis until the time of this 
study. Uberlândia is a city located in the western region of 
the State of Minas Gerais, Brazil. The strains were isolated 
from various clinical samples (cerebrospinal fluid [CSF], 
blood, skin lesion secretions and bronchoalveolar lavage). 
The study was carried out after been approved by the 
Ethics Committee of the Federal University of Uberlândia 
(UFU), under number 357.803, in 08.13.2013. In the 
Microbiology Laboratory of the HCU, the phenotypic 
identification of Cryptococcus spp. is routinely carried 
out using classical phenotypic tests such as the hydrolysis 
of urea and canavanine glycine bromothymol blue agar 
(CGB). To ensure the viability of the strains, they were 
maintained on Sabouraud Dextrose agar (SDA) at room 
temperature with quarterly subcultures. These stored strains 
were evaluated in this study. 
To evaluate the epidemiological profile of patients 
who had developed cryptococcosis, we studied patient 
charts. They were analyzed to gather data on demographics 
(gender, age, base disease, immunosuppression causes, CD4 
lymphocyte count, treatment and outcome of the disease) 
and the primary isolation site of Cryptococcus sp. 
Antifungal susceptibility was identified using the 
VITEK® 2 system (Biomérieux), according to the 
manufacturer’s instructions. The inoculum suspension was 
prepared from cultures in SDA, incubated for 48 hours at 
35 oC, with turbidity adjusted to the standard number 2 of 
McFarland. This suspension was transferred to cassettes of 
a susceptibility test card system (AST-YS01, Ref. 22108). 
The cassettes were inserted in the system and the minimal 
inhibitory concentration (MIC) levels were determined in an 
automated equipment. The results were expressed in µg/mL. 
The concentrations of drugs in the cassettes ranged 
from 1 to 32 µg/mL for amphotericin B, 1 to 16 µg/mL 
for fluconazole, from 4 to 64 µg/mL for 5-flucytosine 
(5FC) and from 0.5 to 8 µg/mL for voriconazole. Candida 
albicans ATCC® 90028 was used as the control. Although 
clinical breakpoints for imidazole derivatives, including 
fluconazole, have not yet been defined in the literature, the 
strains with a MIC < 8 µg/mL were considered susceptible 
to fluconazole14. 
Although one of the aims of this study was to explore 
the molecular characteristics of Cryptococcus neoformans, 
phenotypic tests were repeated before performing the 
molecular characterization. These tests were conducted after 
recovery of the isolates through three serial subcultures, 
incubated for 72 hours. The phenotypic identification of 
the strains was performed in the last subculture using the 
same tests described previously (classical phenotypic tests).
Molecular tests were carried out after the extraction 
of genomic DNA, according to Bolano et al.15, with 
the modifications advised by Pedroso et al.16. Mating 
types and molecular types were determined. To establish 
the mating type, two pairs of primers were used as 
described by Chatuverdi et al.17: MATα [MATαF 
(5’-CTTCACTGCCATCTTCACCA-3’); MATαR 
(5’-GACACAAAG GGTCATGCCA-3’)], and MATa 
[MATaF (5’-CGCCTTCACTGCTACCTTCT-3’); and 
MATαR (5’-AACGCAAGAGTAAGTCGGGC-3’)]. 
Amplification reactions were performed in a final volume 
of 25 µL, each tube containing 25 ng of genomic DNA, 
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enzyme buffer 1X (Uniscience, São Paulo, Brazil), 1.5 
mM magnesium chloride (Uniscience, São Paulo, Brazil), 
0.2 mM of each dNTP (Ludwig Biotec, RS, Brazil), 
20 picomoles of each primer, and 1 U Taq polymerase 
(Uniscience, SP, Brazil). The amplification conditions were: 
initial denaturation at 94 °C for 4 minutes, 34 cycles at 94 
ºC for 1 minute, 63 ºC and 60 ºC for 1 minute, respectively, 
for MATα or MATa, extension at 72 ºC for 1 minute, 
followed by a final extension at 72 °C for 10 minutes. 
Reactions were kept at 4 ºC. The amplification products 
generated from the PCR reactions were subjected to agarose 
gel electrophoresis in 1% TBE (Tris, Boric acid, EDTA) 
0.5X plus 5 µL/mL fluorescent dye Easy View (Easy Path, 
SP, Brazil), using 5 µL of the amplified product run at 75 
V for 90 minutes. Then, the gel was visualized using an 
ultraviolet transilluminator (L-Pix HE, Loccus do Brasil, 
SP, Brazil) and photographed using the Lab-Image ID photo 
documentation system (Loccus do Brasil, SP, Brazil). The 
presence of amplified fragments of 101 bp and 117 bp was 
considered positive for α and a types, respectively. For the 
results analysis, strains of C. neoformans INCQS 40123 
(ATCC® 28957) and C. neoformans ATCC® 28958 were 
used as controls for α and a types, respectively. 
Amplification reactions for URA-5 gene were performed 
as described in the literature18,19, with a final volume of 
25 µL containing 50 ng of genomic DNA, 1X enzyme buffer 
(Uniscience, São Paulo, Brazil), 1.5 mM magnesium chloride 
(Uniscience, SP, Brazil), 0.2 mM of each dNTP (Ludwig 
Biotec, RS, Brazil), 20 picomoles of each primer URA-5 
(5’-ATGTCCTCCCAAGCCCTCG ACTCCG-3’) and SJ01 
(5’-TTAAGACCTCTGAACACCGTACTC-3’); and 1 U of 
Taq polymerase (Uniscience, SP, Brazil). Reaction conditions 
were: initial denaturation at 94 °C for 4 minutes, 34 cycles 
at 94 °C for 1 minute, annealing at 57 °C for 1 minute, 
extension at 72 °C for 1 minute, followed by a final extension 
at 72 °C for 10 minutes. Samples were kept at 4 °C. Thirty 
microliters of the reaction amplicon were doubly digested 
with Sau96I (10 U/µL) and HhaI (20 U/µL) (New England 
Biolabs, Uniscience, SP, Brazil), and incubated at 37 °C for 
3 hours. The fragments were separated on 3% agarose gel at 
100 V for 5 hours18. We used the controls VNI (serotype A), 
VNII (serotype A), VNII (serotype AD), VNIV (serotype D) 
and VGI-VGIV (C. gattii) for the interpretation and analysis 
of results (Figure 1). 
Data were described (in terms of frequencies and 
percentages) by means of an entry table for each variable, 
as well as by using dual input tables. Associations were 
evaluated using the likelihood ratio test20. The level of 
significance was set at 5% (p < 0.05). The statistical 
procedures were performed using the SPSS software v. 20 
(IBM, NY, USA).
RESULTS
Of the 41 patients evaluated, there were seven women 
(17%) and 34 men (83%). Most patients were aged from 20 
to 40 years; most women were in the 20-30 years old group 
(Table 1). There was no statistically significant difference 
between men and women in relation to age (p > 0.05). 
Table 2 shows the distribution of patients according 
to the underlying disease. Most of them (35 [90%]) were 
immunocompromised. In 35 patients (85%) the underlying 
Figure 1 - RFLP profiles (URA5 genes) from C. neoformans/C. gattii control strains. Columns 1 and 13: molecular markers 
(100 bp); columns 2 to 5: genotypes VNI, VNII, VNIII and VNIV, respectively; columns 6 to 9: genotypes VGI, VGII, VGIII and VGIV, 
respectively; column 10 is URA5 gene amplified product; columns 11 and 12 are clinical isolates Cryptococcus neoformans VNI 
and Cryptococcus gattii VGI, respectively.
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Cryptococcal meningoencephalitis was the predominant 
clinical form of cryptococcosis: in 21 (51%) the fungus was 
isolated from the CSF only, eight (19%) from the blood 
culture only, 10 (24%) from the CSF and blood culture, one 
(3%) from the secretions of skin lesions, and one (3%) from 
the bronchoalveolar lavage (BAL) (Table 3).
Thirty-five patients (85%) received antifungal therapy, 
and all of them were treated with amphotericin B; 
fluconazole was used in 25 patients (71%) during the 
consolidation phase. The remaining patients (15%) died 
before treatment.
The lethality of cryptococcosis was estimated at 58.5%. 
Among the patients who died, most had isolated fungemia or 
fungemia associated with meningoencephalitis (p = 0.001). 
Among the 35 patients with AIDS, 21 (60%) died; among 
the four patients with other causes of immunosuppression 
(all male), one (25%) died; however, there was no statistical 
difference (p=0.133) between the evolution of disease in 
the AIDS patients compared to those with other causes 
of immunosuppression (Table 4). There was no statistical 
difference regarding the clinical outcome of men and 
women (p = 0.935). 
Table 5 shows some characteristics of cryptococcosis 
regarding the clinical outcome of patients.
All the isolates were susceptible to the tested antifungal 
agents, showing a MIC < 8 µg/ mL for fluconazole. 
Most isolates (97.6%) were genotyped as C. neoformans 
var. grubii (serotype A, VNI genotype). However, one 
isolate (2.4%) previously phenotyped as C. neoformans 
(positive urea hydrolysis test and negative CGB test) was 
genotyped as C. gattii (VGI genotype) (Figure 2). All the 
strains presented the MATα mating type.
DISCUSSION 
This study has evaluated cases of cryptococcosis 
occurring at the Uberlândia Clinical Hospital from 2004 
to 2013. Most patients (68%) were aged between 20-40 
years (both genders) and had AIDS. The Brazilian Health 
Table 2 - Distribution of underlying diseases associated with 
cryptococcosis in patients treated at the HCU, 2004-2013
Base Disease
Frequency
n %
AIDS 35 85.0
Chronic alcohol abuse 1 2,5
Leprosy+Rheumatoid arthritis 1 2.5
Hypertension + gout 1 2.5
Psoriatic arthritis 1 2.5
Not reported 2 5.0
Total 41 100%
Table 3 - Distribution of clinical forms of cryptococcosis according to the isolation site from patients treated at the HCU, 2004-2013 
Clinical Form
Frequency
Isolation site
N %
Meningoencephalitis 21 51.2 CSF
Cutaneous cryptococcosis 1 2.5 Skin lesion secretion
Fungaemia 8 19.5 Blood
Meningoencephalitis + fungaemia 10 24.3 CSF+blood
Pulmonary cryptococcosis 1 2.5 BAL
Total 41 100
Table 1 - Frequency of cryptococcosis according to the age and 
the gender of patients treated at the HCU, 2004-2013
AGE 
(years)
GENDER
MALE FEMALE
n % n %
20-30 10 29.4 3 42.8
31-40 14 41.2 1 14.3
41-50 6 17.6 1 14.3
51-60 1 2.9 0 0.0
61-69 1 2.9 2 28.6
> 70 2 6.0 0 0.0
Total 34 82.9 7 17.1
disease was AIDS. Other diseases were chronic alcohol 
abuse, rheumatoid arthritis, leprosy, psoriatic arthritis, 
hypertension and gout; patients with these diseases were 
chronic corticosteroids or other immunosuppressive drugs 
users. In two patients, there was no evidence of immune 
impairment in their medical records. 
Among AIDS patients, 17 had a CD4 lymphocyte count 
< 200 cells/ mm3, with values ranging from 5-196 cells/ mm3. 
In other patients, this exam was not performed during the 
hospitalization period.
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Ministry21 data indicates the highest prevalence of AIDS in 
patients between 25 and 39 years in both genders. Brazilian 
studies show the highest prevalence of cryptococcosis in 
this age group, with slight variations concerning the age 
groups 20-30 years and 31-40 years22,23. Mezzari et al.24 
studied the epidemiology of cryptococcosis in a public 
hospital in Rio Grande do Sul, Brazil and reported that 
most patients were aged 30-39 years. Patients in this age 
group were born and raised in the period coinciding with 
the emergence and spread of HIV, which was accompanied 
by changes in sexual behavior, including increased number 
of partners, thereby contributing to the spread of HIV and 
of opportunistic infections such as cryptococcosis. 
In Brazil, cryptococcosis occurs as the first manifestation 
of an opportunistic disease in over 4% of AIDS patients, 
and is as one of its defining illnesses10. The present study 
contained more men (83%) than women. According to 
the AIDS Epidemiological Bulletin21 data, there was an 
increase of 4.3% in the detection rates of the disease in 
men during the study period, while there was a significant 
decrease (14%) among women. Moreira et al.25 studied 
the epidemiology of cryptococcosis in the HCU and also 
reported a higher prevalence of the disease in males, with 
a similar percentage in the present study. According to 
Carvour et al.26, despite the predominance in males, women 
with meningoencephalitis have a worse prognosis than 
men, with lower survival rates. In this study there was no 
Table 4 - Clinical outcome of patients with cryptococcosis treated at the HCU from 2004 to 2013 
Clinical 
outcome
Patients
TOTALMALE FEMALE
NR HIV+ HIV- NR HIV+ HIV-
n % n % n % n % n % n % n %
Survived 0 0.0 11 32.0 3 9.0 0 0.0 3 43.0 0 0 17 41.5
Died 1 3.0 18 53.0 1 3.0 1 14.0 3 43.0 0 0 24 58.5
TOTAL 1 3.0 29 85.0 4 12.0 1 14.0 6 86.0 0 0 51 100.0
NR: Not reported; HIV: Human Immunodeficiency Virus
Table 5 - Comparison of variables according to the clinical outcome of patients with cryptococcosis treated at the HCU from 2004 
to 2013 
Variables
Clinical evolution 
Total (41) p valueSURVIVED (17) DIED (24)
N % n % n
Male 14 41.2 20 51.8 34 0.935
AIDS 14 40.0 21 60.0 35 0.133
Meningoencephalitis 15 48.3 16 51.7 31 0.025
Fungemia 0 0.0 8 100.0 8 0.001
Pulmonary form 1 100.0 0.0 0.0 1 0.180
Treatment 17 48.6 18 51.4 35 0.008
Fluconazol 15 60.0 10 40.0 25 0.028
Amphotericin B 15 42.8 20 57.2 35 0.082
Figure 2 - RFLP profile of the URA5 genes from 
Cryptococcus sp obtained by double-digestion with HhaI and 
Sau96I. Column 1: Molecular maker (100 bp). Columns 2 to 
7: isolated 2, 4, 5, 6, 7 and 8 (VNI), respectively; column 8: 
isolated 12 (VGI); Columns 9 to 13: isolates 13, 18, 22, 24 
and 25 (VNI), respectively. 
Aguiar et al.
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significant difference between men and women in relation 
to prognosis and survival. 
All 39 patients (95%) with a documented immune status 
were immunocompromised and most were AIDS patients (35 
[90%]). C. neoformans infections in immunocompromised 
hosts are widely described in the literature27,28,29. Among 
the AIDS patients, only 17 (48.5%) had CD4/CD8 T 
lymphocyte counts recorded in their medical notes, and 
most had been previously diagnosed with AIDS. These 
patients had less than 200 cells/mm3 and, in 15 of them 
(88%), the count was less than 100 cells/mm3. In a cohort 
study of 700 patients, Jarvis et al.30 observed an increased 
risk of meningoencephalitis when patients had CD4 
counts below 100 cells/mm3. The WHO31 recommends 
screening with the Cryptococcus antigen test (CRAG) in 
AIDS patients who have CD4 counts below 100 cells/mm3. 
In those who have tested positive, treatment with 
fluconazole should be promptly initiated in order to prevent 
cryptococcosis. These recommendations, however, are not 
based on clinical evidence32.
Accord ing  to  the  Braz i l ian  Consensus  on 
Cryptococcosis10, in over 80% of the cryptococcosis cases, 
the predominant clinical form is meningoencephalitis. The 
fungus was detected in the CSF of 31 patients (75%) in the 
present study; many studies have shown meningoencephalitis 
to be the predominant clinical form3,23,25,28,33,34,35,36. In eight 
patients (19%), the fungus was found only in the blood. 
Studies have shown that fungemia by Cryptococcus spp. 
may be present in 47-71% of AIDS patients. However, this 
percentage is 27% among those not infected by HIV27. In 
this study, of the eight patients with isolated fungemia, six 
(75%) had AIDS. The other two patients had no medical 
report regarding their immune status. All the patients (10 
[24%]) in whom the fungus was present in the CSF and 
blood, as detected by culture, had AIDS. 
Thirty-five patients received specific treatment for 
cryptococcosis with drugs available in Brazil (amphotericin 
B and fluconazole) according to the management guidelines 
of the disease10,37,38. Amphotericin B was started for all the 
patients; however, 10 (28.5%) died in the early induction 
phase before fluconazole could be started (during the 
consolidation phase). Six patients (14%) who had fungemia 
received no treatment because, we believe, they presented 
a serious initial clinical form of disease with hemodynamic 
instability. In these patients, the diagnosis of cryptococcosis 
was made only after the fungus was isolated in their blood 
cultures, and this occurred post mortem. Of these untreated 
patients, four (66%) had AIDS and the immune status of 
the other two was unknown.
In the present study, the overall mortality associated with 
cryptococcosis was high and demonstrates the severity of 
the disease, despite the use of specific treatment. In Brazil, 
according to the literature, mortality rates range from 26% 
to 70%23,24,25,39; in the present study the mortality rate was 
58.5%. The factors that influence this outcome include the 
virulence of C. neoformans, the slow response to treatment 
with amphotericin B, the advanced stage of the patients 
immunosuppression (particularly those with AIDS), and the 
superimposition of opportunistic infections, for example, 
neurotoxoplasmosis, pneumocystosis, that have worsened 
clinical conditions.
In Brazil, studies of the in vitro susceptibility of 
Cryptococcus spp. have shown that most isolates are 
susceptible to polyene antifungals, 5-flucytosine and 
azoles10. However, the in vivo resistance of C. neoformans 
to imidazole derivatives (especially to fluconazole) is well 
documented in the literature, especially in patients with 
AIDS who have meningoencephalitis and who use this 
drug for prolonged periods10,11,40. Silva et al.41 suggested 
that treatment failure can occur due to the development 
of resistance to amphotericin B. Nevertheless, the present 
study found that all the isolates were susceptible in vitro 
to the tested drugs. The reference methodology indicated 
by CLSI42 to perform antifungal susceptibility tests to 
C. neoformans used the microdilution broth method, but 
Tweari et al.43 found that the technique used by Vitek®2 
shows good accuracy for antifungal susceptibility testing, 
particularly to fluconazole and amphotericin, presenting an 
agreement level with the reference methodology of 80% 
and 90%, respectively. 
C. neoformans var. grubii has been isolated from various 
environmental sources and from clinical samples. In Brazil, 
this species is prevalent in the Southeastern and Southern 
States2. In the present study, all the identified isolates as 
C. neoformans comprised var. grubii (serotype A, VNI 
genotype). This confirms the prevailing distribution of this 
species in the State of Minas Gerais18,22. Some studies 
indicate that over 80% of cases of cryptococcosis are caused 
by var. grubii, mostly in AIDS patients44,45. 
All the isolates considered in this study were mating type 
MATα, a finding consistent with the literature46. Desnos-
Ollivier et al.28 studied 400 samples of C. neoformans 
(serotype A-244, serotype D-76 and serotype AD-70) 
isolated in France and found no MAT a sample in serotype 
A (all of them were MATα); only 13 serotype D samples 
were MATa.
This study demonstrates the importance of using 
molecular methods in the correct identification of clinical 
isolates. One of the isolates previously identified as C. 
neoformans presented a VGI genotype, showing that it was 
actually the species C. gattii. This isolate gave a negative 
CGB test result. This is an interesting finding because 
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the results from epidemiological studies based only on 
classical techniques can diverge from those based on the 
most accurate methods. In general, clinical laboratories use 
the CGB test to distinguish between the two major species, 
C. neoformans and C. gattii. This test has been routinely 
used in laboratories since its proposal in 198247. Despite 
being a simple biochemical test that is relatively rapid 
(requiring 10 days of incubation), although expensive, the 
CGB may result in reactions that are difficult to interpret, 
generating both, false positive and false negative results48. 
The correlation between the molecular identification and 
the CGB test varies according to the study, from 95.4% to 
100%49,50. Some studies45,51,52 suggest that the phenotypic 
identification of Cryptococcus spp. must be confirmed 
by molecular techniques such as RFLP-PCR, which for 
C. neoformans enables serotype and molecular typing at 
the same time. Although the use of molecular methods to 
identify the species of Cryptococcus may still be infrequent 
in routine microbiology laboratories, these have become 
efficient alternatives, being more sensitive, specific, timely, 
and being less influenced by external factors than the 
traditional phenotypic methods18,19,51,53.
In summary, in this study, cryptococcosis was most 
prevalent in male patients with AIDS and, despite the 
institution of appropriate drug therapy, most patients died. 
C. neoformans var. grubii (VNI genotype) was the main 
etiological agent, and all of the isolates showed in vitro 
susceptibility to the tested antifungal agents. It is worth 
noting the growing importance of molecular methods for 
the proper identification of Cryptococcus species, since 
traditional phenotypic methods may fail.
CONTRIBUTIONS
All the authors participated in drafting and reviewing 
the paper and made relevant contributions. They have all 
given their final approval to, and agreed to be accountable 
for, all the aspects of the study.
ACKNOWLEDGMENTS
We thank the clinical analysis laboratories of HCU, and 
the technical team from the Technical School of Health 
(ESTES), Federal University of Uberlândia (UFU), for 
the physical space and supplies to accomplish this work. 
Érika Bezerra de Melo Riceto and Ralciane Paula Menezes 
for their technical support in some experiments. Mario 
Leon Silva Vergara, Délio José Mora Amador Júnior and 
Leonardo Eurípedes de Andrade e Silva, from Triângulo 
Mineiro Federal University (UFTM), for providing the 
control isolates VNI and VGI; and Luciana Trilles, from 
Oswaldo Cruz Foundation (FIOCRUZ), for providing the 
molecular types reference strains. 
CONFLICT OF INTERESTS
None.
REFERENCES
 1.  Lacaz CS, Porto E, Martins JE, Heins-Vaccari EM, Melo NT. 
Criptococose. In: Lacaz CS, editor. Tratado de micologia 
médica. 9ª ed. São Paulo: Sarvier; 2002.
 2.  Pappalardo MC, Melhem MS. Cryptococcosis: a review of the 
Brazilian experience for the disease. Rev Inst Med Trop Sao 
Paulo. 2003;45:299-305.
 3.  Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas 
PG, Chiller TM. Estimation of the current global burden of 
cryptococcal meningitis among persons living with HIV/AIDS. 
AIDS. 2009;23:525-30.
 4.  Bicanic T, Harrison TS. Cryptococcal meningitis. Br Med Bull. 
2005;72:99-118.
 5.  Kwon-Chung KJ, Varma A. Do major species concepts support 
one, two or more species within Cryptococcus neoformans? 
FEMS Yeast Res. 2006;6:574-87.
 6.  Del Poeta M, Casadevall A. Ten challenges on Cryptococcus and 
cryptococcosis. Mycopathologia. 2012;173:303-10.
 7.  Casadevall A, Perfect JR. Cryptococcus neoformans. Washington: 
ASM Press; 1998.
 8.  Lengeler KB, Cox GM, Heitman J. Serotype AD strains of 
Cryptococcus neoformans are diploid or aneuploid and 
are heterozygous at the mating-type locus. Infect Immun. 
2001;69:115-22.
 9.  Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, 
Fyfe M, et al. A rare genotype of Cryptococcus gattii 
caused the cryptococcosis outbreak on Vancouver Island 
(British Columbia, Canada). Proc Natl Acad Sci U S A. 
2004;101:17258-63.
 10.  Consenso em criptococose - 2008. Rev Soc Bras Med Trop. 
2008;41:524-44.
 11.  Cheong JW, McCormack J. Fluconazole resistance in cryptococcal 
disease: emerging or intrinsic? Med Mycol. 2013;51:261-9.
 12.  Smith KD, Achan B, Hullsiek KH, McDonald TR, Okagaki 
LH, Alhadab AA, et al. Increased antifungal drug resistance 
in clinical isolates of Cryptococcus neoformans in Uganda. 
Antimicrob Agents Chemother. 2015;59:7197-204.
 13.  Magalhães YC, Bomfim MR, Melônio LC, Ribeiro PC, Cosme 
LM, Rhoden CR, et al. Clinical significance of the isolation of 
Candida species from hospitalized patients. Braz J Microbiol. 
2015;46:117-23.
 14.  Espinel-Ingroff A, Aller AI, Canton E, Castaño-Olivares LR, 
Chowdhary A, Cordoba S, et al. Cryptococcus neoformans-
Aguiar et al.
Rev Inst Med Trop São Paulo. 2017;59:e13Page 8 of 9
Cryptococcus gattii species complex: an international 
study of wild-type susceptibility endpoint distributions and 
epidemiological cutoff values for fluconazole, itraconazole, 
posaconazole, and voriconazole. Antimicrob Agents 
Chemother. 2012;56:5898-906.
 15.  Bolano A, Stinchi S, Preziosi R, Bistonin F, Allegrucci M, 
Baldelli F, et al. Rapid methods to extract DNA and RNA from 
Cryptococcus neoformans. FEMS Yeast Res. 2001;1:221-4.
 16.  Pedroso RS, Lavrador MA, Ferreira JC, Candido, RC, Maffei 
CM. Cryptococcus neoformans var. grubii – Pathogenicity 
of environmental isolates correlated to virulence factors, 
susceptibility to fluconazole and molecular profile. Mem Inst 
Oswaldo Cruz. 2010;105:993-1000.
 17.  Chatuverdi S, Rodeghier B, Fan J, Mc Clelland CM, Wickles BL, 
Chatuverdi V. Direct PCR of Cryptococcus neoformans MAT α 
and MAT a pheromones to determine mating type, ploidy, and 
variety: a tool for epidemiological and molecular pathogenesis 
studies. J Clin Microbiol. 2000;38:2007-9.
 18.  Meyer W, Castañeda A, Jackson S, Huynh M, Castañeda E. 
Molecular typing of Iberoamerican Cryptococcus neoformans 
isolates. Emerg Infect Dis. 2003;9:189-95.
 19.  Mora DJ, Pedrosa AL, Rodrigues V, Leite Maffei CM, Trilles 
L, Dos Santos Lazéra M, et al. Genotype and mating type 
distribution within clinical Cryptococcus neoformans and 
Cryptococcus gattii isolates from patients with cryptococcal 
meningitis in Uberaba, Minas Gerais, Brazil. Med Mycol. 
2010;48:561-9.
 20.  Agresti A. An introduction to categorical data analysis. 2nd ed. 
New York: John Wiley & Sons; 2007.
 21.  Brasil. Ministério da Saúde. Boletim epidemiológico HIV-AIDS. 
Brasília: Ministério da Saúde; 2014.
 22.  Leal AL, Faganello J, Fuentefria AM, Boldo JT, Bassanesi 
MC, Vainstein MH. Epidemiological profile of cryptococcal 
meningitis patients in Rio Grande do Sul, Brazil. 
Mycopathologia. 2008;166:71-5.
 23.  Mora DJ, da Cunha Colombo ER, Ferreira-Paim K, Andrade-
Silva LE, Nascentes GA, Silva-Vergara ML. Clinical, 
epidemiological and outcome features of patients 
with cryptococcosis in Uberaba, Minas Gerais, Brazil. 
Mycopathologia. 2012;173:321-7.
 24.  Mezzari A, Wliebbeling AM, Freitas GS, May GG, Albé GC, 
Filik HP, et al. Criptococose em um hospital público de Porto 
Alegre: dados epidemiológicos. J Infect Control. 2013;2:135-9.
 25.  Moreira TA, Ferreira MS, Ribas MR, Borges AS. Criptococose: 
estudo clínico-epidemiológico, laboratorial e das variedades do 
fungo em 96 pacientes. Rev Soc Bras Med Trop. 2006;39:255-8.
 26.  Carvour ML, Harms JP, Lynch CF, Mayer RR, Meier JL, Liu D, et 
al. Differential survival for men and women with HIV/AIDS-
related neurologic diagnoses. PLoS One. 2015;10:e0123119.
 27.  Antinori S. New insights into HIV/AIDS-associated 
cryptococcosis. ISRN AIDS. 2013;2013:471363.
 28.  Desnos-Ollivier M, Patel S, Raoux-Barbot D, Heitman J, 
Francoise D. Cryptococcosis serotypes impact outcome and 
provide evidence of Cryptococcus neoformans speciation. 
MBio. 2015;6:e00311.
 29.  Idnurm A, Lin X. Rising to the challenge of multiple Cryptococcus 
species and the diseases they cause. Fungal Genet Biol. 
2015;78:1-6.
 30.  Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T, Harrison 
TS. Adult meningitis in a setting of high HIV and TB 
prevalence: findings from 4961 suspected cases. BMC Infect 
Dis. 2010;10:67.
 31.  World Health Organization. Rapid advice: diagnosis, prevention 
and management of cryptococcal disease in HIV–infected 
adults, adolescents and children. Geneva: WHO; 2011.
 32.  Masur H. HIV-related opportunistic infections are still relevant 
in 2015. Top Antivir Med. 2015;23:116-9.
 33.  Lindenberg AS, Chang MR, Paniago AM, Lazéra MS, Moncada 
PM, Bonfim GF, et al. Clinical and epidemiological features 
of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil. 
Rev Inst Med Trop Sao Paulo. 2008;50:75-8.
 34.  Pappas PG. Cryptococcosis in the developing world: an elephant 
in the parlor. Clin Infect Dis. 2010;50:345-6.
 35.  Pappas PG. Cryptococcal infections in non-HIV-infected patients. 
Trans Am Clin Climatol Assoc. 2014;123:61-79.
 36.  Sloan DJ, Parris V. Cryptococcal meningitis: epidemiology and 
therapeutic options. Clin Epidemiol. 2014;6:169-82.
 37.  Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill 
JR, Hamill RJ, et al. Clinical practice guidelines for the 
management of cryptococcal disease: 2010 update by the 
Infectious Diseases Society of America. Clin Infect Dis. 
2010;50:291-322.
 38.  Perfect JR, Bicanic T. Cryptococcosis diagnosis and treatment: 
what do we know now. Fungal Genet Biol. 2015;78:49-54.
 39.  Souza LK, Costa CR, Fernandes OF, Abrão FY, Silva TC, Treméa 
CM, et al. Clinical and microbiological features of cryptococcal 
meningitis. Rev Soc Bras Med Trop. 2013;46:343-7.
 40.  Friese G, Discher T, Füssle R, Schmalreck A, Lohmever 
J. Development of azole resistance during fluconazole 
maintenance therapy for AIDS-associated cryptococcal 
disease. AIDS. 2001;15:2344-5.
 41.  Silva PR, Rabelo RA, Terra AP, Teixeira DN. Suscetibilidade 
a antifúngicos de variedades de Cryptococcus neoformans 
isoladas de pacientes em hospital universitário. Rev Soc Bras 
Med Trop. 2008;41:158-62.
 42.  Clinical and Laboratory Standards Institute. Reference method for 
broth dilution antifungal susceptibility testing of yeasts: third 
informational supplement. Wayne: Clinical and Laboratory 
Standards Institute; 2008.
 43.  Tewari A, Behera B, Mathur P, Xess I. Comparative analysis of the 
Vitek 2 Antifungal Susceptibility System and E-test with the 
CLSI M27-A3 broth microdilution method for susceptibility 
Rev Inst Med Trop São Paulo. 2017;59:e13
The epidemiology of cryptococcosis and the characterization of Cryptococcus neoformans
Page 9 of 9
testing of Indian clinical isolates of Cryptococcus neoformans. 
Mycopathologia. 2012;173:427-33.
 44.  Perfect JR, Casadevall A. Cryptococcosis. Infect Dis Clin North 
Am. 2002;16:837-74.
 45.  Meyer W, Trilles L. Genotyping of the Cryptococcus neoformans/C. 
gattii species complex. Australian Biochemist. 2010;41:12-5.
 46.  Kwon-Chung KJ, Edman JC, Wickes BL. Genetic association 
of mating types and virulence in Cryptococcus neoformans. 
Infect Immun. 1992;60:602-5.
 47.  Kwon-Chung KJ, Bennett JE. Medical mycology. Philadelphia: 
Lea & Febiger; 1992.
 48.  Khan ZU, Al-Anezi AA, Chandy R, Xu J. Disseminated 
cryptococcosis in an AIDS patient caused by a canavanine-
resistant strain of Cryptococcus neoformans var. grubii. J Med 
Microbiol. 2003;52:271-5.
 49.  Klein KR, Hall L, Deml SM, Rysavy JM, Wohlfiel SL, 
Wengenack NL. Identification of Cryptococcus gattii by use 
of L-canavanine glycine bromothymol blue medium and DNA 
sequencing. J Clin Microbiol. 2009;47:3669-72.
 50.  Gomes, FS, Santo EP, Sarmento DN, Silva, SH. Quimiotipagem 
e caracterização fenotípica de Cryptococcus. Rev Pan-Amaz 
Saude. 2010;1:43-9.
 51.  Trilles L, Lazéra MS, Wanke B, Oliveira RV, Barbosa GG, 
Nishikawa MM, et al. Regional pattern of the molecular type 
of Cryptococcus neoformans and Cryptococcus gattii in Brazil. 
Mem Inst Oswaldo Cruz. 2008;103:455-62.
 52.  Trilles L, Wang B, Firacative C, Lazéra MS, Wanke B, Meyer W. 
Identification of the major molecular types of Cryptococcus 
neoformans and C. gattii by hyperbranched rolling circle 
amplification. PLoS One. 2014;9:e94648.
 53.  Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov 
E, et al. Recognition of seven species in the Cryptococcus 
gattii/Cryptococcus neoformans species complex. Fungal 
Genet Biol. 2015;78:16-48.
